Timing of Sodium–Glucose Cotransporter 2 Inhibitor Initiation and Post-Discharge Outcomes in Acute Heart Failure with Diabetes: A Population-Based Cohort Study
Real-world evidence supports early SGLT2 inhibitor initiation to reduce HHF or cardiovascular mortality in acute heart failure and type 2 diabetes.
Authors
- Jodi D. Edwards (ORCID: https://orcid.org/0000-0002-9275-4787)
- Refik Saskin (ORCID: https://orcid.org/0000-0002-8641-7725)
- Che‐Yuan Wu (ORCID: https://orcid.org/0000-0001-8548-1824)
- Alexander Kopp (ORCID: https://orcid.org/0000-0001-8787-0401)
- Baiju R. Shah (ORCID: https://orcid.org/0000-0003-3598-3628)
- Walter Swardfager (ORCID: https://orcid.org/0000-0002-0030-8908)
- Peter P. Liu (ORCID: https://orcid.org/0000-0002-3017-1199)
- Abhinav Sharma (ORCID: https://orcid.org/0000-0001-5084-5165)
- Yiru Sheng
Institutions
- Sunnybrook Health Science Centre (CA)
- University Health Network (CA)
- University of Ottawa (CA)
- University of Toronto (CA)
- Toronto Rehabilitation Institute (CA)
- McGill University Health Centre (CA)
- Health Sciences Centre (CA)
- Ottawa Public Health (CA)
- Ontario Brain Institute (CA)
- Sunnybrook Research Institute
Publication Details
- Journal
- European Journal of Heart Failure
- Published
- 2024-09-12
- DOI
- https://doi.org/10.1002/ejhf.3464
- Citations
- 6
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.15
Funders
- AstraZeneca
- Heart and Stroke Foundation of Canada
- Fondation Brain Canada
- Canadian Bee Research Fund
- Canadian Cardiovascular Society
- Government of Canada
- European Society of Cardiology
- Canada Research Chairs
- University of Toronto
- Novo Nordisk
- Alberta Innovates
- Canada First Research Excellence Fund
- Servier
- Ministry of Colleges and Universities
- Health Canada
- Canadian Institutes of Health Research
- Temerty Faculty of Medicine, University of Toronto